Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing Into Liver Cirrhosis and Tumors
Authors:
- Qianqian ZhengQZQianqian Zheng
- Masaya KawaguchiMKMasaya Kawaguchi
- Hayato MikamiHMHayato Mikami
- Pan DiaoPDPan Diao
- Xuguang ZhangXZXuguang Zhang
- Zhe ZhangZZZhe Zhang
- Takero NakajimaTNTakero Nakajima
- Takanobu IwadareTITakanobu Iwadare
- Takefumi KimuraTKTakefumi Kimura
- Jun NakayamaJNJun Nakayama
- Naoki TanakaNaoki Tanaka
Preprint
- 2 May 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Non-alcoholic steatohepatitis (NASH), which is the most severe manifestation of non-alcoholic fatty liver disease (NAFLD), has been recognized as a major hepatocellular carcinoma (HCC) catalyst. However, the molecular mechanism of NAFLD-NASH-HCC sequence remains unclear and a specific and effective treatment for NASH has not yet been established. The progress in this field depends on the availability of reliable preclinical models which show the steady progress to NASH, liver cirrhosis, and HCC. However, most of NASH mouse models that have been described to date develop NASH generally for more than 24 weeks and there is an uncertainty of HCC development. To overcome such shortcomings of experimental NASH studies, we established a novel NASH-HCC mouse model with very high reproducibility, generality, and convenience. We treated male C57BL/6J mice with a newly developed choline-deficient and methionine-restricted high-fat diet (CDMRHFD) for 60 weeks. Treatment of CDMRHFD for 3 weeks revealed marked steatosis, lobular inflammation, and fibrosis, histologically diagnosed as NASH. Liver cirrhosis was observed in all mice with 36-week treatment. Liver nodule emerged at 12 weeks of the treatment, and diameter >2 mm liver tumors developed in all mice at 24 weeks of the treatment. In conclusion, our rapidly progressive and highly reproducible NASH-liver cirrhosis-HCC model is helpful for preclinical development and research on the pathogenesis of human NAFLD-NASH-HCC. Our mouse model would be useful for the development of novel chemistry for NASH-HCC-targeted therapies or HCC prevention strategies.Keywords
All Related Versions
- Version 1, 2023-05-02, Preprints
- Published version: Cancers, 15 (14), 3744.
This publication has 40 references indexed in Scilit:
- Pemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver diseaseClinical Journal of Gastroenterology, 2021
- Growth arrest and DNA damage-inducible 45α protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient dietBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2017
- The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiotaHepatology, 2015
- Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient dietBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in miceHepatology, 2013
- Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomyJournal of Gastroenterology, 2011
- Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty ConnectionHepatology, 2010
- Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator‐activated receptor α in transgenic mice: Implications for HCV‐associated hepatocarcinogenesisInternational Journal of Cancer, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical backgroundJournal of Gastroenterology, 2003